Analytical Data
-
基因名
F8A1
- Application
-
别名
F8A; F8A2; F8A3; HAP40; int22h; Factor VIII intron 22 Protein(intronic transcript); CpG Island Protein
-
种属
Mouse
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q00558
-
表达区间
His171~Pro375
-
分子量
26kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
F8A1 recombinant protein research focuses on the development and application of a synthetic version of a key protein involved in blood coagulation, specifically Factor VIII. Factor VIII is essential for normal blood clotting, and its deficiency or dysfunction leads to hemophilia A, a hereditary bleeding disorder characterized by increased bleeding tendency. Traditional treatments for hemophilia A involved infusions of human-derived Factor VIII, which carried risks such as viral transmission and immune responses. The advent of recombinant DNA technology has allowed for the production of F8A1, a non-modified, highly purified version of Factor VIII, in various expression systems. This innovation aims to provide a safer, more effective treatment option with consistent quality and reduced risks. Researchers are investigating the structure, function, and stability of F8A1 recombinant protein, exploring its efficacy in therapies to restore normal clotting function in hemophilia A patients. Furthermore, studies focus on optimizing production processes and understanding the protein's interactions with other factors in the coagulation cascade, thus enhancing its therapeutic potential and paving the way for improved treatment strategies in hemophilia management.
